Login
From:
Sleep Review
(Uncensored)
subscribe
Alkermes Orexin Receptor Agonist Shows Broad Benefits in Phase 2 Narcolepsy Study | Sleep Review
https://sleepreviewmag.com/sleep-treatments/pharmaceuticals/emerging-compounds/alkermes-orexin-receptor-agonist-broad-benefits-phase-2-narcolepsy-study/
links
backlinks
Tagged with:
clinical trials
narcolepsy
phase 2
emerging compounds
alkermes
orexin
Alkermes’ alixorexton met primary and key secondary endpoints in a phase 2 trial for narcolepsy type 1, showing dose-dependent improvements.
Roast topics
Find topics
Find it!
